Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V502 in HPV-related diseases
NCT00365443Phase 2Withdrawn
- Sponsor
- Merck & Co.
- Start
- Oct 2006
- Modality
- Recombinant Protein Vaccines
01
Overview
Phase 2, randomised, double-blind trial of octavalent HPV L1 VLP vaccine in Cervical Cancer (CC), vulvar cancer, vaginal cancer and 1 more, sponsored by Merck & Co. Primary endpoint: Prevention of cervical, vulvar, and vaginal cancers and related precancers, external genital lesions, and persistent infection. Planned start Oct 2006; status: withdrawn.
02
Drugs
octavalent HPV L1 VLP vaccine
03
Conditions
Cervical Cancer (CC)vulvar cancervaginal cancercondylomata acuminata
Beyond the preview
Go deeper on NCT00365443.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00365443.